Opendata, web and dolomites


Next generation cancer therapies targeting cancer networks

Total Cost €


EC-Contrib. €






Project "CancerQR" data sheet

The following table provides information about the project.


Organization address
city: BASEL
postcode: 4056
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PATTERN BIOSCIENCES GMBH CH (BASEL) coordinator 50˙000.00


 Project objective

'Pattern BioSciences is an ETH Zurich Spin-Off and an innovative biotechnology start up that proposes a paradigm shifting approach towards tailored and customizable cancer therapies. The company is commercializing the disruptive 'Network against Network' approach to cancer therapies, which takes into account tumor complexity and probes and targets tumor cells at multiple points of tumor molecular network. The therapies will be more efficacious, less toxic and less prone to drug resistance compared to the state of the art treatments. Building on large IP portfolio and extensive expertise and know-how of its founders, the company proposes this feasibility study to assess the commercialization potential of its offering via intensive partner search, stakeholder alignment, freedom to operate analysis, and formulating IPR and knowledge management strategy. With company's current Minimal Viable Product (MVP) at TRL 6, interaction with prospective parters during this feasibility study will define the set of Customizable Therapeutic Prototypes (CTPs) at TRL 9, conducive to entering into partnership deals. Delivering CTPs in the Phase II of the innovation action will enable the company to enter into large scale, long term partnership agreements with established players in Pharma and Biotech industries and execute a European-wide growth and expansion plan, creating multiple jobs and strengthening Europe as an innovative Biotechnology hub.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANCERQR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANCERQR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ChromicGlass (2019)


Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

Close (2019)

Redefining the customer journey of live event visitors

Read More